Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant TumorsPurpose
The purpose of this study is to find the highest dose of the investigational drug DS-7300a that can be given safely in patients with advanced solid tumors. DS-7300a is an antibody-drug conjugate. The antibody part binds to a protein called BH-73, which many advanced solid tumors make and which helps them survive and grow. Once bound to a cancer cell, the drug part of DS-7300a is released and kills cancer cells. DS-7300a is given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
Patients must have an advanced solid tumor that cannot be successfully treated with standard therapies. Examples include head and neck cancers, esophageal cancer, non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, prostate cancer, and breast cancer.
Patients should recover from the serious side effects of previous treatments before receiving DS-7300a.
Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Claire Friedman at 646-888-4247.